Compile Data Set for Download or QSAR
Report error Found 1256 Enz. Inhib. hit(s) with all data for entry = 11514
TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622041(US20230312550, Example 1 | (R)-N-(2-(4-Cyanothiazo...)
Affinity DataKoff:  7.30E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622041(US20230312550, Example 1 | (R)-N-(2-(4-Cyanothiazo...)
Affinity DataKon:  0.000140M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622042(US20230312550, Example 2)
Affinity DataKoff:  4.10E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622042(US20230312550, Example 2)
Affinity DataKon:  0.00380M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622043(US20230312550, Example 3)
Affinity DataKoff:  4.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622043(US20230312550, Example 3)
Affinity DataKon:  0.000400M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622044(US20230312550, Example 4)
Affinity DataKoff:  1.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622044(US20230312550, Example 4)
Affinity DataKon:  0.0000940M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622046(US20230312550, Example 6)
Affinity DataKoff:  4.00E+10s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622046(US20230312550, Example 6)
Affinity DataKon:  18M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622047(US20230312550, Example 7)
Affinity DataKoff:  7.40E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622047(US20230312550, Example 7)
Affinity DataKon:  0.0000750M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622048(US20230312550, Example 8)
Affinity DataKoff:  1.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622048(US20230312550, Example 8)
Affinity DataKon:  0.0000340M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622049(US20230312550, Example 9)
Affinity DataKoff:  1.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622049(US20230312550, Example 9)
Affinity DataKon:  0.000760M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622050(US20230312550, Example 10)
Affinity DataKoff:  3.70E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622050(US20230312550, Example 10)
Affinity DataKon:  0.0000560M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622052(US20230312550, Example 12)
Affinity DataKoff:  1.90E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622052(US20230312550, Example 12)
Affinity DataKon:  0.0000640M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622053(US20230312550, Example 13)
Affinity DataKoff:  9.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622053(US20230312550, Example 13)
Affinity DataKon:  0.0000760M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622054(US20230312550, Example 14)
Affinity DataKoff:  1.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622054(US20230312550, Example 14)
Affinity DataKon:  0.0000640M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622055(US20230312550, Example 15)
Affinity DataKoff:  4.90E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622055(US20230312550, Example 15)
Affinity DataKon:  0.0000460M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622056(US20230312550, Example 16)
Affinity DataKoff:  7.40E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622056(US20230312550, Example 16)
Affinity DataKon:  0.0000410M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622057(US20230312550, Example 17)
Affinity DataKoff:  8.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622057(US20230312550, Example 17)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622058(US20230312550, Example 18)
Affinity DataKoff:  1.40E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622058(US20230312550, Example 18)
Affinity DataKon:  0.0000590M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622059(US20230312550, Example 19)
Affinity DataKoff:  4.30E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622059(US20230312550, Example 19)
Affinity DataKon:  0.0000660M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622060(US20230312550, Example 20)
Affinity DataKoff:  4.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622060(US20230312550, Example 20)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622061(US20230312550, Example 21)
Affinity DataKoff:  3.00E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622061(US20230312550, Example 21)
Affinity DataKon:  0.000200M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622062(US20230312550, Example 22)
Affinity DataKoff:  9.40E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622062(US20230312550, Example 22)
Affinity DataKon:  0.0000470M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622063(US20230312550, Example 23)
Affinity DataKoff:  2.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622063(US20230312550, Example 23)
Affinity DataKon:  0.000180M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622064(US20230312550, Example 24)
Affinity DataKoff:  2.50E+7s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622064(US20230312550, Example 24)
Affinity DataKon:  0.000480M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622065(US20230312550, Example 25)
Affinity DataKoff:  1.40E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622065(US20230312550, Example 25)
Affinity DataKon:  0.000110M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622066(US20230312550, Example 26)
Affinity DataKoff:  1.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622066(US20230312550, Example 26)
Affinity DataKon:  0.0000650M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622067(US20230312550, Example 27)
Affinity DataKoff:  1.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622067(US20230312550, Example 27)
Affinity DataKon:  0.0000260M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1256 total ) | Next | Last >>
Jump to: